On June 27, 2018, the U.S. FDA approved BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for the treatment of patients with wild-type BRAF melanoma. This means now, physicians and patients have the option to consider treatment with this combination therapy.
Posted at 1:34 PM, Jan 02, 2019
and last updated 2019-01-02 13:34:55-05
Copyright 2019 Scripps Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.